Have your own idea? Try our Stock Screener
Japanese (NIKKEI) Biotech Industry Analysis
UpdatedFeb 25, 2026
DataAggregated Company Financials
Companies34
- 7D-2.0%
- 3M6.1%
- 1Y4.1%
- YTD15.9%
Over the last 7 days, the Biotech industry has dropped 2.0%, driven by Cuorips declining 38%. In contrast, GNI Group has gained 7.1%. Over the past 12 months, the industry was up 4.1%. Looking forward, earnings are forecast to grow by 43% annually.
Industry Valuation and Performance
Has the Japanese Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Wed, 25 Feb 2026 | JP¥1.2t | JP¥200.5b | -JP¥50,373,794,682.00 | 294.9x | -23.3x | 5.8x |
| Fri, 23 Jan 2026 | JP¥1.1t | JP¥198.7b | -JP¥70,406,297,000.00 | 63.1x | -15.7x | 5.6x |
| Sun, 21 Dec 2025 | JP¥953.3b | JP¥198.7b | -JP¥70,727,642,000.00 | 53.9x | -13.5x | 4.8x |
| Tue, 18 Nov 2025 | JP¥1.1t | JP¥194.6b | -JP¥68,862,746,000.00 | 52.1x | -15.6x | 5.5x |
| Thu, 16 Oct 2025 | JP¥1.2t | JP¥197.7b | -JP¥65,794,561,000.00 | 63.3x | -18.2x | 6.1x |
| Sat, 13 Sep 2025 | JP¥1.2t | JP¥197.7b | -JP¥66,441,862,000.00 | 67.6x | -17.9x | 6x |
| Mon, 11 Aug 2025 | JP¥1.2t | JP¥191.4b | -JP¥67,600,768,000.00 | 128x | -17.6x | 6.2x |
| Wed, 09 Jul 2025 | JP¥1.1t | JP¥218.2b | -JP¥43,671,220,000.00 | 98.3x | -24.4x | 4.9x |
| Fri, 06 Jun 2025 | JP¥1.2t | JP¥214.8b | -JP¥40,595,705,000.00 | 14.8x | -30.3x | 5.7x |
| Sun, 04 May 2025 | JP¥1.1t | JP¥207.8b | -JP¥39,129,850,000.00 | 15x | -27.5x | 5.2x |
| Tue, 01 Apr 2025 | JP¥1.0t | JP¥207.8b | -JP¥39,285,612,000.00 | 15.9x | -26.5x | 5x |
| Thu, 27 Feb 2025 | JP¥1.1t | JP¥207.4b | -JP¥38,725,942,000.00 | 15.3x | -27.5x | 5.1x |
| Sat, 25 Jan 2025 | JP¥994.6b | JP¥207.3b | -JP¥13,514,452,000.00 | 20.8x | -73.6x | 4.8x |
| Mon, 23 Dec 2024 | JP¥1.0t | JP¥206.4b | -JP¥12,718,809,000.00 | 22.4x | -82x | 5.1x |
| Wed, 20 Nov 2024 | JP¥1.0t | JP¥207.5b | -JP¥10,805,549,000.00 | 19.8x | -94.4x | 4.9x |
| Fri, 18 Oct 2024 | JP¥1.1t | JP¥214.3b | -JP¥3,941,738,000.00 | 22x | -283.8x | 5.2x |
| Sun, 15 Sep 2024 | JP¥1.0t | JP¥210.1b | -JP¥469,229,000.00 | 18.5x | -2218.2x | 5x |
| Tue, 13 Aug 2024 | JP¥948.4b | JP¥213.8b | JP¥1.8b | 13.9x | 516.5x | 4.4x |
| Thu, 11 Jul 2024 | JP¥1.1t | JP¥187.7b | -JP¥15,773,047,000.00 | 93x | -67.1x | 5.6x |
| Sat, 08 Jun 2024 | JP¥828.3b | JP¥195.7b | -JP¥14,113,284,000.00 | 96.5x | -58.7x | 4.2x |
| Mon, 06 May 2024 | JP¥801.3b | JP¥199.1b | -JP¥14,617,545,000.00 | 77.4x | -54.8x | 4x |
| Wed, 03 Apr 2024 | JP¥749.5b | JP¥194.2b | -JP¥15,458,035,000.00 | 63.3x | -48.5x | 3.9x |
| Fri, 01 Mar 2024 | JP¥843.4b | JP¥196.2b | -JP¥19,179,997,000.00 | 67.3x | -44x | 4.3x |
| Sun, 28 Jan 2024 | JP¥779.2b | JP¥222.3b | -JP¥12,604,827,000.00 | 17.6x | -61.8x | 3.5x |
| Tue, 26 Dec 2023 | JP¥773.1b | JP¥224.2b | -JP¥12,970,409,000.00 | 16.4x | -59.6x | 3.4x |
| Thu, 23 Nov 2023 | JP¥787.4b | JP¥221.9b | -JP¥12,426,487,000.00 | 17.2x | -63.4x | 3.5x |
| Sat, 21 Oct 2023 | JP¥741.7b | JP¥223.0b | -JP¥14,478,735,000.00 | 20.5x | -51.2x | 3.3x |
| Mon, 18 Sep 2023 | JP¥875.3b | JP¥223.0b | -JP¥14,518,735,000.00 | 27.6x | -60.3x | 3.9x |
| Wed, 16 Aug 2023 | JP¥862.8b | JP¥225.0b | -JP¥17,523,776,000.00 | 50.1x | -49.2x | 3.8x |
| Fri, 14 Jul 2023 | JP¥926.8b | JP¥223.0b | -JP¥19,224,669,000.00 | 53.9x | -48.2x | 4.2x |
| Sun, 11 Jun 2023 | JP¥967.6b | JP¥220.6b | -JP¥21,578,670,000.00 | 46.3x | -44.8x | 4.4x |
| Tue, 09 May 2023 | JP¥908.9b | JP¥218.2b | -JP¥20,061,938,000.00 | 21x | -45.3x | 4.2x |
| Thu, 06 Apr 2023 | JP¥929.3b | JP¥218.3b | -JP¥21,583,164,000.00 | 21x | -43.1x | 4.3x |
| Sat, 04 Mar 2023 | JP¥923.3b | JP¥216.2b | -JP¥18,991,580,000.00 | 20.7x | -48.6x | 4.3x |
Price to Earnings Ratio
-48.6x
Current Industry PE
- Investors are optimistic on the Japanese Biotechs industry, and appear confident in long term growth rates.
- The 3-year average PS ratio of 4.7x is lower than the industry's current PS ratio of 5.8x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have deteriorated over the last three years.
- Revenues have also declined 2.5% per year.
- This means overall sales from these companies are declining and losses are subsequently expanding as well.
Industry Trends
Which industries have driven the changes within the Japanese Healthcare industry?
| JP Market | 1.37% | |
| Healthcare | 3.80% | |
| Biotech | -1.99% | |
| Biotech | -1.99% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 2160 GNI Group | JP¥2.97k | 7.1% +JP¥11.0b | -20.5% | PS6.2x | |
| 4588 Oncolys BioPharma | JP¥2.71k | 10.5% +JP¥7.6b | 292.5% | PS2777.1x | |
| 7774 Japan Tissue Engineering | JP¥700.00 | 12.2% +JP¥3.1b | 40.3% | PS12.6x | |
| 4978 ReproCELL | JP¥183.00 | 9.6% +JP¥1.5b | 0% | PS6.9x | |
| 4587 PeptiDream | JP¥1.40k | 0.7% +JP¥1.3b | -32.0% | PS9.8x |
